Novo Nordisk ( Novo Nordisk )

Novo Nordisk

Novo Nordisk's picture

About Novo Nordisk

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries. Novo Nordisk is controlled by majority shareholder, Novo A/S, which holds approximately 25% of its shares and a majority 75% voting shares.

Novo Nordisk press release, blog etc

11/05/2018 - 17:37 Novo Nordisk A/S purchases B shares worth DKK 1,262 million from Novo Holdings A/S under the 2018 share repurchase programme
11/02/2018 - 08:21 Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease
11/01/2018 - 05:40 Novo Nordisk's operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018
10/31/2018 - 06:31 Novo Nordisk expands its biopharm business with the acquisition of the US and Canadian rights to Macrilen(TM)
10/26/2018 - 04:21 Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin
10/15/2018 - 07:54 Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm
10/12/2018 - 18:10 Fiasp is effective at controlling blood sugar levels in children and adolescents living with type 1 diabetes, when compared to conventional insulin aspart
10/02/2018 - 01:05 Ryzodeg offers a simpler solution with once-daily dosing and reduced risk of nocturnal hypoglycaemia vs insulin glargine U100 plus insulin aspart
10/01/2018 - 23:58 People with diabetes may achieve improved glycaemic control with Tresiba versus glargine U100, without an increase in hypoglycaemia
10/01/2018 - 23:32 Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention
10/01/2018 - 07:42 Novo Nordisk to establish California manufacturing site for stem cell-based therapies
10/01/2018 - 07:30 Novo Nordisk plans first global launch of connected insulin pens and announces key digital health partnerships
09/27/2018 - 19:27 International Diabetes Federation (IDF) global survey reveals 2 in 3 people with type 2 diabetes have cardiovascular disease risk factors and/or have experienced a cardiovascular event
09/27/2018 - 18:51 New phase 2 data for somapacitan demonstrate its potential as an efficacious once-weekly treatment for childhood growth hormone deficiency
09/23/2018 - 22:08 Danish Government and Novo Nordisk first to partner with UN-anchored initiative on non-communicable diseases
09/20/2018 - 11:08 Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes
09/18/2018 - 11:13 Novo Nordisk announces plans to transform its approach to Research & Development
08/26/2018 - 09:43 Ozempic consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline